Navigation Links
Varian Medical Systems Schedules First Quarter FY2011 News Release and Conference Call
Date:12/20/2010

PALO ALTO, Calif., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) announced today that it will report results for first quarter of fiscal year 2011 following the close of regular trading on Wednesday, January 26, 2011.  The news release will be followed by a teleconference available to all interested parties at 2:00 p.m. PT.  The news release and a link to the conference call webcast will be available on the company website at: www.varian.com/investor.  To access the teleconference call and replay:Teleconference:

Access from within the U.S. by dialing 1-800-901-5226, and from outside the U.S. by dialing 1-617-786-4513, and entering code 58660413.Replay:

Access from within the U.S. by dialing 1-888-286-8010 and from outside the U.S. by dialing 1-617-801-6888, and entering code 98071883. The teleconference will be rebroadcast until 8:00 p.m. ET, Friday, January 28, 2011.Webcast:

Visit the company website at: www.varian.com/investor and click on the "Quarterly Conference Call" icon. Web conferences will be archived on the company website for a year.  For automatic "e-mail alerts" regarding Varian news and events, investors can subscribe on the company website: http://varian.investorroom.com/index.php?s=58.   For additional information contact Anne Rambo at 650-424-5834 or anne.rambo@varian.com

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radi
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014   West Pharmaceutical Services, Inc. ... in innovative solutions for injectable drug administration, announced today ... include a new site in Waterford, Ireland ... for insulin injector cartridges and other high-value packaging components, ... biotech customers. Once operational, this new site could bring ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014  Abaxis, Inc. ... manufacturing point-of-care instruments and consumables for the medical, research, ... to the veterinary and research markets in ... entered into a definitive distribution agreement with Patterson Veterinary ... and promote the full line of Abaxis veterinary products ...
(Date:10/1/2014)... JUPITER, Fla. , Oct. 1, 2014 /PRNewswire/ ... biotechnology company with patented and proprietary technology used ... for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial ... $500,000 licensing payment from Abengoa Bioenergy for commercial ... for converting biomass into ethanol, developed under Abengoa,s ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... 9, 2007 -,GlaxoSmithKline (LSE and NYSE:GSK) and ... 767905/014 and,provided an update on the clinical ... Phase 3, double blind, placebo-controlled (12,month) study, ... and,tolerability of alvimopan 0.5 mg twice daily ...
... Educate on Good,Diabetes Management and How to Reduce ... 10, 2007 /PRNewswire/ -- A first-of-its-kind,report looking at ... shows that an estimated three out of five ... least one of the other,serious health problems commonly ...
Cached Medicine Technology:GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7
(Date:10/2/2014)... October 02, 2014 Recently, BambooIndustry.com, a ... its new collection of bamboo floors . What’s ... a lot of its products at the moment. According ... up to 26 percent off. The promotion will be ... floors ( http://www.bambooindustry.com ) are all made by qualified ...
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product ... great appreciation from the global customers in the past ... make more excellent items. All its online workers are ... clients. , The company has recently added a ... website. Furthermore, the company’s marketing specialist has announced that ...
(Date:10/2/2014)... with autism are more sedentary than those without the ... a small study suggests. Researchers tested the fitness ... and some without. Children with autism averaged 50 fewer ... more minutes each day sitting than those without autism. ... strength, but had similar body-mass index (a measurement of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... Columbia now have a total of 500 confirmed cases of ... children since the summer, U.S. health officials reported Wednesday. ... recent weeks, but it,s not clear what role -- if ... Health officials are also trying to determine if the ...
(Date:10/1/2014)... research study published today in the Journal of ... older than 50 years with moderate or severe chronic ... Researchers from the University of Melbourne randomly assigned 282 ... to no acupuncture or sham or pretend laser treatment. ... participants and acupuncturists blinded to laser and sham (inactive) ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2
... spending on medical research in Europe should be doubled ... welfare for Europes citizens and to nurture a thriving ... between European institutions in medical research and improved career ... the main recommendations of the European Medical Research Councils ...
... VICTORVILLE, Calif., Feb. 5 Dr. Richard Merkin ... Senior,Valentine,s Day Luncheon. They will host this special luncheon ... Victorville Senior Hall., The event is open to ... down,meal from Carino,s Italian Grill and entertainment by the ...
... more likely than nonsmokers to report lack of restful slumber, ... are four times more likely to feel tired when they ... than nonsmokers do, a new study finds. , This may ... contribute to sleep disturbances, suggest the study authors, whose report ...
... finding turned out to be a clue leading researchers ... to propose a new treatment approach for Niemann-Pick disease, ... the genetic defect in Niemann-Pick disease, the researchers suggest ... through the cell,s quality control machinery. And they believe ...
... Agency has finalised an agreement with an ESA-led ... which contributes to the premature deaths of hundreds ... agreement, the European Environment Agency (EEA) will use ... with surface measurements from 29 European countries to ...
... 5 Keystone Human Services (KHS),is pleased ... Inc., a privately,owned, Pennsylvania based for-profit agency ... autism for 35 years. Impact,Systems, Inc., serving ... will become an important component of,Keystone,s regional ...
Cached Medicine News:Health News:Collaboration needed for strengthening medical research in Europe 2Health News:Smokers Sleep Less Soundly 2Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3Health News:Satellite data to deliver 'state-of-the-art' air quality information 2Health News:Keystone Human Services Acquires Impact Systems, Inc. 2
Straight shafts with 1 x 2 teeth. Serrated handle, non-magnetic and polished finish....
Straight shafts with pointed 4.5 mm tying surfaces. Scalloped wide handle with dull finish....
Straight shafts with 0.5 mm teeth and 6 mm tying platform. Wide serrated handle with thumb catch lock and polished finish....
Angled 45 degree shafts 8 mm long with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: